{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:05Z","timestamp":1791357245430,"version":"4.3.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.clinthera.2012.03.002","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T01:02:53Z","timestamp":1334019773000},"page":"1023-1040","source":"Crossref","is-referenced-by-count":30,"title":["Asenapine: A Clinical Review of a Second-Generation Antipsychotic"],"prefix":"10.1016","volume":"34","author":[{"given":"Steven C.","family":"Stoner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.03.002_bib1","first-page":"369","article-title":"Treatment of schizophrenia: let's talk dollars and sense [published correction appears in Am J Manag Care. 1998;4:611]","volume":"4","author":"Buckley","year":"1998","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2012.03.002_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.03.002_bib3","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2012.03.002_bib4","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/00023210-200822080-00004","article-title":"Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden","volume":"22","author":"Faglioni","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2012.03.002_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4088\/JCP.v64n0111","article-title":"Screening for bipolar disorder in the community","volume":"64","author":"Hirschfeld","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib9","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.03.002_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second vs. first generation antipsychotic drugs in schizophrenia","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib12","series-title":"Clozaril (colazapine) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.03.002_bib13","series-title":"Risperdal (risperidone) [package insert]","year":"2011"},{"key":"10.1016\/j.clinthera.2012.03.002_bib14","series-title":"Zyprexa (olanzapine) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.03.002_bib15","series-title":"Seroquel and Seroquel XR (quetiapine) [package insert]","year":"2011"},{"key":"10.1016\/j.clinthera.2012.03.002_bib16","series-title":"Geodon (ziprasidone) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.03.002_bib17","series-title":"Abilify (aripiprazole) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.03.002_bib18","series-title":"Risperdal Consta (risperidone) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.03.002_bib19","series-title":"Invega and Invega Sustenna (paliperidone) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.03.002_bib20","series-title":"Saphris (asenapine) [package insert]","year":"2011"},{"key":"10.1016\/j.clinthera.2012.03.002_bib21","series-title":"Fanapt (Iloperidone) [package insert]","year":"2010"},{"key":"10.1016\/j.clinthera.2012.03.002_bib24","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/j.1742-1241.2009.02228.x","article-title":"Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2012.03.002_bib25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","article-title":"A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disorders"},{"key":"10.1016\/j.clinthera.2012.03.002_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","article-title":"Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial","volume":"122","author":"McIntyre","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1016\/j.clinthera.2012.03.002_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-5618.2009.00749.x","article-title":"Asenapine versus olanzapine in acute mania: a double-bind extended treatment of bipolar mania","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disorders"},{"key":"10.1016\/j.clinthera.2012.03.002_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","article-title":"Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study","volume":"126","author":"McIntyre","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1016\/j.clinthera.2012.03.002_bib29","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0030-1248313","article-title":"Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder","volume":"43","author":"Schoemaker","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","article-title":"A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment","volume":"72","author":"Kane","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2012.03.002_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1331\/JAPhA.2010.10505","article-title":"New drugs: asenapine, iloperidone, and bepotastine besilate","volume":"50","author":"Hussar","year":"2010","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.clinthera.2012.03.002_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"2391","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2012.03.002_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-008-1456-5","article-title":"Asenapine elevates cortical dopamine, noradrenaline, and serotonin release","volume":"204","author":"Franberg","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.clinthera.2012.03.002_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.euroneuro.2008.11.001","article-title":"Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, alpha-2 adrenergic and D2 receptors in the rat brain","volume":"19","author":"Ghanbari","year":"2009","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2012.03.002_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00213-008-1098-7","article-title":"Differential regional and dose-related effects of asenapine on dopamine receptor subtypes","volume":"198","author":"Tarazi","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.clinthera.2012.03.002_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-007-0973-y","article-title":"Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia","volume":"196","author":"Franberg","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.clinthera.2012.03.002_bib38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/dmd.110.036715","article-title":"Metabolism and excretion of asenapine in healthy male subjects","volume":"39","author":"van de Wetering-Krebbers","year":"2011","journal-title":"Drug Metab Disposition"},{"key":"10.1016\/j.clinthera.2012.03.002_bib39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11200860-000000000-00000","article-title":"Asenapine","volume":"23","author":"Weber","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2012.03.002_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2012.03.002_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/syn.20618","article-title":"Asenapine exerts distinctive regional effects on inotropic glutamate receptor subtypes in rat brain","volume":"63","author":"Tarazi","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.clinthera.2012.03.002_bib42","series-title":"Atypical Antipsychotics","first-page":"163","article-title":"Dopamine receptor subtypes and schizophrenia: a clinical perspective","author":"Den Boer","year":"2000"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2012.03.002_bib43","first-page":"S4452","article-title":"Asenapine pharmacokinetics: influence of cytochrome P450 modulators and UDP-glucuronyltransferase inhibition","volume":"18","author":"Dogterom","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2012.03.002_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/11590490-000000000-00000","article-title":"Asenapine pharmacokinetics in hepatic and renal impairment","volume":"50","author":"Peeters","year":"2011","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812001518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812001518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T03:03:11Z","timestamp":1561604591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812001518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0149291812001518"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.03.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}